AZALEA-TIMI 71 is a phase 2b, multicenter, randomized, active-controlled study to evaluate the safety and tolerability of two blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban in patients with atrial fibrillation. MAIN RESULTS:Abelacimab versus Rivaroxaban in Patients with Atrial FibrillationN Engl J Med. 2025 Jan 23;392(4):361-371.   MAIN RESULTS PRESENTATION … Continue reading AZALEA-TIMI 71